Clinical trial
A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)
NCT05409183 is registered in ClinicalTrials.gov with Cardurion Pharmaceuticals, Inc. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 2, Randomized, Double-Blind, Placebo-Controlled Clinical Study to Assess the Effectiveness of CRD-740 in Subjects With Chronic Heart Failure (CARDINAL-HF)
- Lead sponsor
- Cardurion Pharmaceuticals, Inc.
- Phase
- Phase 2
- Overall status
- Terminated
- Start date
- May 26, 2022
- Completion date
- July 25, 2023
- Enrollment
- 60 (actual)
- Sites
- 34
Conditions
As the registry lists them; a condition with its own page is linked.
cardiovascular diseases, heart diseases, heart failure, heart failure with preserved ejection fraction, heart failure with reduced ejection fraction